Abstract # 3163 Poster # 109:

Scheduled for Saturday, September 17, 2011 07:00 PM-09:00 PM: Session 14 (Salon G (Sixth Floor)) Poster Presentation


GLARGINE TO TREAT DIET INDUCED TYPE II DIABETES MELLITUS IN SINGLY HOUSED RHESUS MACAQUES (MACACA MULATTA).

A. Kostrba, L. Pranger, J. Welch, P. Kievit and K. L. Grove
Oregon National Primate Research Center, 505 NW 185th , Beaverton , Oregon 97006, USA
line
     

The trend towards obesity in humans strongly highlights the need for an obese macaque model. These animals have healthcare needs that mirror the obese human population, including treatment for diabetes. Glargine, a long acting form of insulin, is extensively used in humans to treat diabetes. It is an ideal insulin choice for macaques because it can be administered once daily; as opposed to the twice daily regimen which require additional handling. In our colony of diet induced obese macaques, six males and one female have progressed to diabetes based on three criteria; fasting glucose level > 100mg/dL, HbA1c > 8.0% and/or glucosauria. Unsedated blood samples were collected monthly pre and post treatment. Samples were analyzed for insulin, glucose, HbA1c, and serum chemistry. The Glargine dosing range tested was 0.5-1.75U/kg. Efficacy was determined by a glucose curve which measures pre and postprandial glucose levels. The optimal dose was achieved when average daily glucose levels were <100mg/dL and HbA1c ?8.0%, which varied by animal depending on the severity of diabetes and islet function. Our studies have shown that Glargine is effective in treating diabetes in diet induced obese macaques by lowering fasting glucose levels and HbA1c in all of our animals. However, in some of our animals Glargine was not sufficient in normalizing daily glucose levels (average <100mg/dL), indicating that additional treatments maybe required.